As part of the recent announcement by BioNTech, the biotech company’s new American Depositary Shares (ADS) will be placed at $ 93 each. In addition to the previously announced 5 million unit certificates, the Mainz company increased the volume of the capital increase by a further 0.5 million. “For stabilization purposes, an existing shareholder has given emission banks a 30-day option in connection with the underwritten offer to purchase another 825,000 ADSs at the same issue price,” continues the company, which is currently collaborating with research partner Pfizer on a vaccine against SARS- CoV-2 Virus developed – the causative agent of the rampant corona pandemic.
The total subscription offer amounts to more than 7.5 million shares – including the ADS. “31 ADS subscription rights entitle their owners to purchase a new ADS. The subscription period for the ADS subscription rights runs from 12:01 p.m. (New York time) on July 28, 2020 to 00:01 a.m. (New York time) on August 14, 2020. The subscription period for the stock subscription rights runs from 00: 00:00 (Mainz time) on July 28, 2020 to 24:00 (Mainz time) on August 14, 2020 ”, says BioNTech about the options – the company’s ADSs are traded on NASDAQ.